<?xml version="1.0" encoding="UTF-8"?><oembed><type>video</type><version>1.0</version><html>&lt;iframe src=&quot;https://www.loom.com/embed/a8baa478d04a44f4a740c38d5aa03e30&quot; frameborder=&quot;0&quot; width=&quot;1298&quot; height=&quot;973&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt;</html><height>973</height><width>1298</width><provider_name>Loom</provider_name><provider_url>https://www.loom.com</provider_url><thumbnail_height>973</thumbnail_height><thumbnail_width>1298</thumbnail_width><thumbnail_url>https://cdn.loom.com/sessions/thumbnails/a8baa478d04a44f4a740c38d5aa03e30-da32ab3ec96302d3.gif</thumbnail_url><duration>86.319</duration><title>Why a Cancer Test Trial Missed Its Endpoint</title><description>This Loom discusses a cancer screening research question audit and why the protocol missed its endpoint. It explains that the problem was the wrong research question for a low prevalence population, where a composite cancer endpoint created many false alarms among the general NHS screening population. The hypothesis that sounded reasonable was reviewed and found to be flawed, with a “phlob of a protocol lock” noted. The logic is that positive tests shift from mostly false alarms in the general population to flipping in a higher risk or richer group, which the trial missed due to question design rather than technology.</description></oembed>